Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure- based virtual screening

被引:27
作者
Atatreh, Noor [1 ]
Ghattas, Mohammad A. [1 ]
Bardaweel, Sanaa K. [2 ]
Al Rawashdeh, Sara [1 ]
Al Sorkhy, Mohammad [1 ]
机构
[1] Al Ain Univ Sci & Technol, Dept Pharmaceut Sci, Coll Pharm, Al Ain, U Arab Emirates
[2] Univ Jordan, Dept Pharmaceut Sci, Sch Pharm, Amman 11942, Jordan
关键词
protein-protein interaction; virtual screening; Mdm2; p53; anticancer; docking; pharmacophore; ELISA; P53-MDM2; INTERACTION; P53; PATHWAY; CANCER; DISCOVERY; DESIGN; POTENT;
D O I
10.2147/DDDT.S182444
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Background: The tumor suppressor protein p53 plays an important role in preventing tumor formation and progression through its involvement in cell division control and initiation of apoptosis. Mdm2 protein controls the activity of p53 protein through working as ubiquitin E3 ligase promoting p53 degradation through the proteasome degradation pathway. Inhibitors for Mdm2-p53 interaction have restored the activity of p53 protein and induced cancer fighting properties in the cell. Purpose: The objective of this study is to use computer-aided drug discovery techniques to search for new Mdm2-p53 interaction inhibitors. Methods: A set of pharmacophoric features were created based on a standard Mdm , inhibitor and this was used to screen a commercial drug-like ligand library; then potential inhibitors were docked and ranked in a multi-step protocol using GLIDE. Top ranked ligands from docking were evaluated for their inhibition activity of Mdm2-p53 interaction using ELISA testing. Results: Several compounds showed inhibition activity at the submicromolar level, which is comparable to the standard inhibitor Nutlin-3a. Furthermore, the discovered inhibitors were evaluated for their anticancer activities against different breast cancer cell lines, and they showed an interesting inhibition pattern. Conclusion: The reported inhibitors can represent a starting point for further SAR studies in the future and can help in the discovery of new anticancer agents.
引用
收藏
页码:3741 / 3752
页数:12
相关论文
共 41 条
[1]   Discovery and Optimization of Chromenotriazolopyrimidines as Potent Inhibitors of the Mouse Double Minute 2-Tumor Protein 53 Protein-Protein Interaction [J].
Allen, John G. ;
Bourbeau, Matthew P. ;
Wohlhieter, G. Erich ;
Bartberger, Michael D. ;
Michelsen, Klaus ;
Hungate, Randall ;
Gadwood, Robert C. ;
Gaston, Rick D. ;
Evans, Bruce ;
Mann, Larry W. ;
Matison, Michael E. ;
Schneider, Stephen ;
Huang, Xin ;
Yu, Dongyin ;
Andrews, Paul S. ;
Reichelt, Andreas ;
Long, Alexander M. ;
Yakowec, Peter ;
Yang, Evelyn Y. ;
Lee, Tani Ann ;
Oliner, Jonathan D. .
JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (22) :7044-7053
[2]   Targeting Apoptosis Pathways for New Cancer Therapeutics [J].
Bai, Longchuan ;
Wang, Shaomeng .
ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 :139-155
[3]   Unravelling mechanisms of p53-mediated tumour suppression [J].
Bieging, Kathryn T. ;
Mello, Stephano Spano ;
Attardi, Laura D. .
NATURE REVIEWS CANCER, 2014, 14 (05) :359-370
[4]   When mutants gain new powers: news from the mutant p53 field [J].
Brosh, Ran ;
Rotter, Varda .
NATURE REVIEWS CANCER, 2009, 9 (10) :701-713
[5]   Rational Design and Binding Mode Duality of MDM2-p53 Inhibitors [J].
de Turiso, Felix Gonzalez-Lopez ;
Sun, Daqing ;
Rew, Yosup ;
Bartberger, Michael D. ;
Beck, Hilary P. ;
Canon, Jude ;
Chen, Ada ;
Chow, David ;
Correll, Tiffany L. ;
Huang, Xin ;
Julian, Lisa D. ;
Kayser, Frank ;
Lo, Mei-Chu ;
Long, Alexander M. ;
McMinn, Dustin ;
Oliner, Jonathan D. ;
Osgood, Tao ;
Powers, Jay P. ;
Saiki, Anne Y. ;
Schneider, Steve ;
Shaffer, Paul ;
Xiao, Shou-Hua ;
Yakowec, Peter ;
Yan, Xuelei ;
Ye, Qiuping ;
Yu, Dongyin ;
Zhao, Xiaoning ;
Zhou, Jing ;
Medina, Julio C. ;
Olson, Steven H. .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (10) :4053-4070
[6]   Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development [J].
Ding, Qingjie ;
Zhang, Zhuming ;
Liu, Jin-Jun ;
Jiang, Nan ;
Zhang, Jing ;
Ross, Tina M. ;
Chu, Xin-Jie ;
Bartkovitz, David ;
Podlaski, Frank ;
Janson, Cheryl ;
Tovar, Christian ;
Filipovic, Zoran M. ;
Higgins, Brian ;
Glenn, Kelli ;
Packman, Kathryn ;
Vassilev, Lyubomir T. ;
Graves, Bradford .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (14) :5979-5983
[7]   Translational approaches targeting the p53 pathway for anti-cancer therapy [J].
Essmann, Frank ;
Schulze-Osthoff, Klaus .
BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (02) :328-344
[8]   How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures [J].
Estrada-Ortiz, Natalia ;
Neochoritis, Constantinos G. ;
Domling, Alexander .
CHEMMEDCHEM, 2016, 11 (08) :757-772
[9]   Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy [J].
Friesner, RA ;
Banks, JL ;
Murphy, RB ;
Halgren, TA ;
Klicic, JJ ;
Mainz, DT ;
Repasky, MP ;
Knoll, EH ;
Shelley, M ;
Perry, JK ;
Shaw, DE ;
Francis, P ;
Shenkin, PS .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (07) :1739-1749
[10]   Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode [J].
Gessier, Francois ;
Kallen, Joerg ;
Jacoby, Edgar ;
Chene, Patrick ;
Stachyra-Valat, Therese ;
Ruetz, Stephan ;
Jeay, Sebastien ;
Holzer, Philipp ;
Masuya, Keiichi ;
Furet, Pascal .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (17) :3621-3625